Effective this month, the coverage applies to approximately 70% of all United Healthcare commercial lives.
United Healthcare has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on the company’s commercial formularies, Kala Pharmaceuticals announced on Tuesday.
Effective this month, the coverage applies to approximately 70% of all commercial lives — 118 million individuals, according to a news release.
Further, Cigna Medicare has also added EYSUVIS as a preferred brand, effective February 2022, Kala stated. With this latest addition, EYSUVIS has coverage via Medicare for select plans with Express Scripts, Prime Therapeutics, and Cigna — totaling 15% of all Medicare lives.
EYSUVIS became commercially available in January 2021. It is the first and only FDA-approved medicine for short-term treatment of the signs and symptoms of dry eye.
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.